Immutep Limited (NASDAQ:IMMP) shares plunged roughly 80% on Friday after the biotechnology company announced it would ...

IMP761 was well tolerated in healthy volunteers when given at single increasing doses, with no safety concerns, according to ...

Immutep (IMMP) stock plunges as the company halts a late-stage trial for its lead asset, eftilagimod alfa due to futility. Read more here.

Immutep has completed the single ascending dose (SAD) portion of its IMP761 study IMP761 was well tolerated across all dose levels IMP761 data ...

Why: Rosen Law Firm, a global investor rights law firm, announces that it is investigating potential securities claims on behalf of shareholders of Immutep Ltd. (NASDAQ: IMMP) resulting from ...

Independent Data Monitoring Committee Recommends Discontinuation of Phase III Trial Following Futility AnalysisSYDNEY, AUSTRALIA, March 13, 2026 ...

Immutep and the Australian biotech’s investors have been caught off guard by the unexpected failure of its LAG-3 candidate in a phase 3 study. The Sydney-based company had been evaluating the ...

SYDNEY, AUSTRALIA, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or "the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, ...